Alto Neuroscience, a clinical-stage biopharmaceutical company based in Los Altos, California, focuses on developing psychiatric drugs using its Precision Psychiatry Platform. The company has five clinical-stage assets targeting depression and schizophrenia, with an IPO on February 2, 2024.
Alto Neuroscience (ANRO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Alto Neuroscience's actual EPS was -$0.62, beating the estimate of -$0.67 per share, resulting in a 6.96% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
